Literature DB >> 11308437

Value of flow diagrams in reports of randomized controlled trials.

M Egger1, P Jüni, C Bartlett.   

Abstract

CONTEXT: Diagrams of the flow of participants through a clinical trial are recommended in the Consolidated Standards for Reporting of Trials (CONSORT) statement, but it is unclear whether such flow diagrams improve the quality of trial reports.
OBJECTIVE: To examine the information contributed by flow diagrams and the completeness of reporting overall in reports of randomized controlled trials (RCTs) published in 5 general and internal medicine journals. DESIGN AND
SETTING: Analysis of 270 reports of RCTs published in 1998 in the Annals of Internal Medicine (AIM; n = 19), BMJ (n = 42), JAMA (n = 45), The Lancet (n = 81), and The New England Journal of Medicine (NEJM; n = 83). MAIN OUTCOME MEASURES: Proportion of reports that included a flow diagram, information provided in flow diagrams, and completeness of reporting about flow of participants overall in flow diagrams or text.
RESULTS: A total of 139 reports (51.5%) of RCTs included a flow diagram, but this varied widely among journals (AIM, 21.0%; BMJ, 38.1%; JAMA, 80.0%; The Lancet, 93.8%; and NEJM, 8.4%). Diagrams generally provided useful information, but only 73 (52.5%) included the number of participants who received allocated interventions and only 32 (23.0%) included the number of participants included in the analysis. In logistic regression analysis, overall completeness of reporting about flow of study participants was associated with publication of a flow diagram.
CONCLUSIONS: Flow diagrams are associated with improved quality of reporting of randomized controlled trials. However, the structure of current flow diagrams is less than ideal. We propose a revised flow diagram that includes all important counts through the stages of parallel group trials.

Entities:  

Mesh:

Year:  2001        PMID: 11308437     DOI: 10.1001/jama.285.15.1996

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  76 in total

1.  How to assess new treatments.

Authors:  R Slinger; D Moher
Journal:  West J Med       Date:  2001-03

2.  Are randomised controlled trials in the BMJ different?

Authors:  M Egger; C Bartlett; P Jüni
Journal:  BMJ       Date:  2001-11-24

Review 3.  Systematic reviews in health care: Assessing the quality of controlled clinical trials.

Authors:  P Jüni; D G Altman; M Egger
Journal:  BMJ       Date:  2001-07-07

4.  Quality of economic evaluations in health care.

Authors:  Tom Jefferson; Vittorio Demicheli
Journal:  BMJ       Date:  2002-02-09

5.  Better standards for better reporting of RCTs.

Authors:  P M Bossuyt
Journal:  BMJ       Date:  2001-06-02

6.  Clinical guidelines online: do they improve compliance?

Authors:  J G Williams; W Y Cheung; D E Price; R Tansey; I T Russell; P D Duane; S A Al-Ismail; M A Wani
Journal:  Postgrad Med J       Date:  2004-07       Impact factor: 2.401

7.  Opportunities and challenges for improving the quality of reporting clinical research: CONSORT and beyond.

Authors:  David Moher; Douglas G Altman; Kenneth F Schulz; Diana R Elbourne
Journal:  CMAJ       Date:  2004-08-17       Impact factor: 8.262

8.  CONSORT statement: extension to cluster randomised trials.

Authors:  Marion K Campbell; Diana R Elbourne; Douglas G Altman
Journal:  BMJ       Date:  2004-03-20

Review 9.  Case-control studies of sporadic enteric infections: a review and discussion of studies conducted internationally from 1990 to 2009.

Authors:  Kathleen E Fullerton; Elaine Scallan; Martyn D Kirk; Barbara E Mahon; Frederick J Angulo; Henriette de Valk; Wilfrid van Pelt; Charmaine Gauci; Anja M Hauri; Shannon Majowicz; Sarah J O'Brien
Journal:  Foodborne Pathog Dis       Date:  2012-04       Impact factor: 3.171

10.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  BMC Med       Date:  2012-05-29       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.